Treace Medical Concepts (TMCI) Depreciation & Amortization (CF) (2020 - 2026)

Treace Medical Concepts has reported Depreciation & Amortization (CF) for 7 years, with the latest figure at $899000.0 in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 63.47% year-over-year to $899000.0; the trailing twelve-month figure through Mar 2026 stood at $9.1 million (up 1.0% YoY), and the FY2025 full-year result was $10.6 million, up 26.18% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $899000.0, down from $2.8 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $2.8 million in Q4 2025, with the low at $300000.0 in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $1.6 million across 5 years, with a median of $1.8 million in 2023.
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) jumped 300.0% — and 2026, when it plunged 63.47%.
• Treace Medical Concepts' Depreciation & Amortization (CF) stood at $917000.0 in 2022, then surged by 92.91% to $1.8 million in 2023, then rose by 26.46% to $2.2 million in 2024, then rose by 25.53% to $2.8 million in 2025, then tumbled by 67.98% to $899000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $899000.0 (Q1 2026), $2.8 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.